Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, phase II, exploratory and multi-centre clinical trial. 37 Limited stage SCLC patients not eligible for concurrent chemo-radiotherapy will be enroll. Patients will be enrolled in the trial after receiving sequential chemo-radiotherapy, if there is no progression disease, patients will be treated with maintenance Tarlatamab. Patients will receive maintenance with Tarlatamab IV until disease progression unacceptable toxicity, patient or physician decision to discontinue or death. The primary objective is to evaluate the Progression free survival (PFS). Patient accrual is expected to be completed within 2 years. Treatment and follow-up are expected to extend the study duration to a total of 5 years. Patients will be followed for 2 years after enrollment. The study will end once survival follow-up has concluded.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór płuc typu SCLC w ograniczonym stadium zaawansowania
- •Ukończona chemioterapia i/lub radioterapia bez pogorszenia się choroby
- •Wiek co najmniej 18 lat
- •Oczekiwana przeżywalność co najmniej 3 miesiące
- •Dobry stan ogólny (skala 0-2)
- •Sprawna funkcja płuc bez konieczności tlenu
- •Normalne parametry pracy serca, wątroby i nerek
- •Pisemna zgoda na udział w badaniu
✗ Disqualifies
- •Zaawansowany typ raka płuc (ES-SCLC) lub inne rodzaje nowotworu
- •Aktywne zaburzenia neurologiczne związane z rakiem
- •Poważna operacja w ostatnie 4 tygodnie
- •Udział w innym badaniu klinicznym w ostatnie 4 tygodnie
- •Poprzedni nowotwór złośliwy (poza SCLC) bez gwarancji pełnego wyleczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (20)
Hospital General Universitario de Albacete
Albacete, Spain
Hospital General Universitario Dr. Balmis de Alicante
Alicante, Spain
Hospital General Universitario de Elche
Elche, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Fundació Althaia
Manresa, Spain
Hospital de Basurto
Bilbao, Spain
Hospital Universitario de Jerez de la Frontera
Jerez de la Frontera, Spain
Hospital Universitario Lucus Augusti
Lugo, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario Puerta de Hierro
Madrid, Spain
Hospital Son Espases
Palma de Mallorca, Spain
Hospital Son Llàtzer
Palma de Mallorca, Spain
Hospital Regional de Málaga
Málaga, Spain
Complejo Hospitalario de Navarra
Pamplona, Spain
Hospital Santa Maria Mai - Complexo Hospitalario Universitario Ourense
Ourense, Spain
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife, Spain
Hospital General Universitario de Valencia
Valencia, Spain
Trial contact
Eva Pereira
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.